Translations:Dipeptidyl peptidase-4 inhibitor/14/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,162 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 17:34, 12 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Dipeptidyl peptidase-4 inhibitor)
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal [[myocardial infarction]], non-fatal [[stroke]] or [[Chronic kidney disease|end-stage renal disease]] when comparing [[metformin]] monotherapy to dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.

A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Dipeptidyl_peptidase-4_inhibitor/14/en&oldid=128227"